ABSTRACT BACKGROUND: Reports of cardiovascular adverse events (AEs) associated with the use of cyclooxygenase-2 inhibitors for the treatment of osteoarthritis (OA) have prompted the quest for a better-tolerated NSAID.
INTRODUCTION
Although nonpharmacologic interventions are the cornerstone of osteoarthritis (OA) management, analgesics are an important component of treatment during the symptomatic periods of the disease. In this respect, current practice guidelines advocate the use of an analgesic (acetaminophen) or an NSAID administered either systemically or topically as first-or second-line drug therapy. 1 However, in view of the cardiovascular adverse events (AEs) associated with the use of cyclooxygenase (COX)-2 inhibitors, a well-tolerated NSAID is needed.
Lornoxicam is an NSAID of the oxicam class with a similar mechanism of action as other oxicams. An in vitro study suggested that lornoxicam is 100 times more potent than tenoxicam as a COX inhibitor. 2 Its analgesic potency is 12 and 10 times greater than that of piroxicam and tenoxicam, respectively. 3 Published clinical trials have documented the effectiveness of lornoxicam as a potent analgesic with excellent antiinflammatory properties in a range of painful and/or inflammatory conditions, including OA.3-5 Lornoxicam has been marketed recently in India, and based on a literature search of MEDLINE (English language; January 2006-June 2008; search terms, lornoxicam, diclofenac, Indians, osteoarthritis), there were no comparative studies in the Indian population.
Therefore, the present study was undertaken to compare the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult Indian patients with OA of the hip or knee.
PATIENTS AND METHODS

STUDY DESIGN
This double-blind, randomized, comparative study was conducted in 5 hospitals across India. The ethical review committees of each participating center (Lokmanya Tilak Municipal Medical College and General Hospital, M R Hospital, Khwaja Banda Nawaz Institute of Medical Sciences, and Grecian Super-Specialty Hospital) approved the study protocol and the informed consent forms. The study was conducted in accordance with the ethical standards for the treatment of patients as outlined in the Declaration of Helsinki.
All eligible patients were provided oral explanations about the nature of the study and about the study drugs. An information sheet was provided in a language understood by each patient before study inclusion. Written informed consent was obtained from each of the participants before study initiation.
I NCLUSION AND EXCLUSION CRITERIA
Patients were enrolled consecutively from the outpatient clinics of each of the participating hospitals. The flowchart in Figure 1 depicts the patient enrollment scheme. Patients who were eligible for the study were Indian men and women aged 30 to 70 years with a diagnosis of OA of the knee or hip confirmed by clinical and diagnostic radiographic criteria. Participants were required to have a diagnosis of functional class I, II, or III according to the American College of Rheumatology Criteria,6,7 which was confirmed by the investigators. Only those patients willing to comply with study procedures and requirements were enrolled in the study. Finally, patients were enrolled if their baseline assessment of arthritis pain was >4 on a visual analog scale (VAS) (0-10 where 0 = no pain and 10 = worst possible pain, or severe or excruciating pain) and if both the patients' and physicians' assessment of arthritis control was poor or very poor.
Patients were excluded from the study if they had a concurrent arthritic condition that might confound or interfere with the evaluation of effectiveness (determined through medical history, laboratory tests, physical examination, and responses to a questionnaire). These included inflammatory arthritis, gout, episodes of acute monoarticular arthritis clinically consistent with pseudogout, Paget's disease affecting the study joint, a history of septic arthritis or intra-articular fracture of the study joint, osteochondritis desiccans or osteonecrosis of the study joint, Wilson's disease, hemochromatosis, ochronosis, or primary osteochondromatosis. Other concurrent medical conditions that resulted in exclusion included severe cardiac, hepatic, renal, or cerebrovascular disease; malignancy; chronic inadequately controlled systemic diseases (eg, diabetes, hypertension, collagen disorders); or any other serious illness. Pregnant and nursing women were also excluded from the study, as were those with symptomatic bursitis or acute joint trauma of the index knee and/or hip. Patients with conditions predisposing them to gastrointestinal dysfunction (eg, a history of peptic ulcer, upper gastrointestinal disease, or ulcerative colitis; smoking; concurrent corticosteroid use; alcohol abuse) were not included in the study. Patients were also excluded if they had a history of bleeding tendencies, cirrhosis, or esophageal varices, or hypersensitivity or allergy to NSAIDs, other COX-2 inhibitors, or sulfonamides. Patients with preexisting asthma, those who would require concomitant drug treatment (eg, lowdose aspirin, warfarin, antiepileptic drugs, fluconazole [inhibitor of cytochrome P450 (CYP) 2C9/3A4}, or ketoconazole [a known inhibitor of CYP3A4}) were also excluded. Patients who had participated in a new drug study in the past 3 months and immunocompromised patients were excluded from the study. Patients with any other condition that, in the opinion of the investigator, might confound the study results or pose a risk to the patient (eg, comorbid conditions for which NSAIDs or paracetamol were contraindicated) were also excluded. The decision to exclude individuals from the study was based on their responses to a questionnaire regarding their health status.
At the screening visit, patients who satisfied the inclusion criteria were required to discontinue their current NSAID treatment. There was a 1-week washout period before the baseline arthritis assessment. No concurrent treatment other than physiotherapy was allowed during the study. Systemic or topical NSAIDs, intra-articular steroids, disease-modifYing drugs, and other experimental forms of treatment were strictly prohibited.
TREATMENT
Patients were randomly assigned to treatment with lornoxicam 8 mg BID or diclofenac 50 mg TID for 4 weeks. The randomization list was computer-generated in a 1: 1 ratio. To maintain blinding of the investigators and patients, the study drugs were packed separately as morning, afternoon, and nighttime doses and were placed in identical sealed containers. Because the recommended dosing regimen is BID for lornoxicam and TID for diclofenac, an additional dummy tablet similar in appearance, taste, and smell to the lornoxicam tablet was provided to maintain blinding in the lornoxicam group.8,9 The randomization code was to be broken only after the analyses were completed.
At the end of the study period, patients were advised to continue the study drugs or to switch to another NSAID at the discretion of the investigator.
Rescue medication in the form of acetaminophen 500-mg tablets (maximum dosage, 2.5 g/d) was permitted for intractable pain in the study joint during the washout period and during the course of the study when pain was not adequately controlled by the study medication. The number of acetaminophen tablets consumed by the patients was recorded at each visit.
EFFICACY ASSESSMENTS
The primary objective of the present study was to assess the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in the treatment of patients with OA. The investigators performed clinical evaluations at outpatient visits at weeks 0 (baseline), 2, and 4 (or at early termination) after the administration of the first dose of the study drugs. The primary end points were the Western Ontario and McMasters Individual Osteoarthritis Index (WOMAC-OA), the WOMAC Composite Index (WOMAC-CI) (for pain, stiffness, and physical function), and VAS scores (for pain). The VAS was presented as a 100-mm or 10-cm horizontal line on which the pain intensity was represented by a point between the extremes of 0 and 10 (where o = no pain and 10 = worst possible pain, or severe or excruciating pain). The patient rated his or her pain on this line while the graduations were hidden. According to the patient's representations, pain was graded and compared before, during, and after treatment. The severity was reported as follows: 0 = no pain, 1 to 3 = mild pain, 4 to 6 = moderate pain, and 7 to 10 = severe pain.
At each visit, patients completed the WOMAC-OA and the WOMAC-CI, a selfadministered questionnaire, consisting of 24 questions (5 regarding pain, 2 regarding stiffness, and 17 regarding physical function) scored on a 5-point scale (where 0 = none and 4 = extreme). Patients' and physicians' global assessment of arthritis control using a 5-point scale (where 0 = very good and 4 = poor) was measured at each visit. The incidence of patient withdrawal and the time to patient withdrawal due to lack of study drug effectiveness were monitored.
SAFETY AND TOLERABILITY ASSESSMENTS
Patients were monitored for laboratory and clinical AEs at each visit. All AEs or unexpected events were recorded in the case record forms. Patients were queried by the investigators for any AEs between study visits. The nature, date of onset, and duration of AEs were recorded. All investigator-reported clinical AEs were recorded at each study visit and evaluated by the investigator for intensity, seriousness, and relationship to the study medication. Severity of an AE was graded by an investigator as follows: 1 = mild (awareness of sign or symptom but easily tolerated); 2 = moderate (discomfort enough to cause interference with usual activity); or 3 = severe (incapacitating, with inability to work or do usual activity). AEs that occurred within 7 days of the last study drug dose and serious AEs that occurred within 30 days of the last study drug dose were included in the safety analyses.
Compliance was monitored throughout the study using a count of the unused medication at each visit.
STATISTICAL ANALYSIS
The sample size calculation assumed a difference of;;,4 between the scores of the 2 groups with lornoxicam and diclofenac. The change from baseline to end point for the lornoxicam group and the diclofenac group was 47.3 and 43.3, respectively, with a standard deviation of 13, 80% power, and an a of 0.05. The primary analysis population was per protocol (PP) population. Patients had to complete the study with a permissible dropout rate of 20% to ensure that 260 completer patients (130/group) would be available in the PP population.
Efficacy variables (changes in scores for pain, stiffness, physical function, WOMAC-CI, VAS, and patients' and physicians' global response to therapy) were analyzed using the Kruskal-Wallis test. The laboratory investigations were analyzed using analysis of variance. Statistical analysis was performed using SPSS version 10.0 (SPSS Inc., Chicago, Illinois). All statistical tests for differences were 2-tailed with a = 0.05. P < 0.05 was considered statistically significant. Data were expressed as mean (SD).
RESULTS
A total of 273 patients (159 men, 114 women; mean [SD} age, 44.73 [l0.72} years; range, 28-68 years) were enrolled in the study (Table I) . One hundred thirty-seven patients received lornoxicam 8 mg BID and 136 received diclofenac 50 mg TID. Seven patients (5.1%) in the lornoxicam group and 6 (4.4%) in the diclofenac group were considered to be dropouts (ie, patients who received the initial dose, but did not return for the subsequent follow-up visits, despite repeated reminders from medical social workers associated with the institutions). Because these patients were considered to be lost to follow-up, their data were not included in the effectiveness and tolerability assessment.
The baseline demographic data of the study patients is shown in Table 1 . The 2 treatment groups were comparable in age, sex, and weight. All vital signs (temperature, pulse rate, respiratory rate, and blood pressure) were within the normal range at baseline. After 4 weeks of treatment, there were no clinically relevant or statistically significant changes in the vital signs. No significant changes were observed in weight for both groups.
A total of 260 patients were included in the analysis: 130 patients received lornoxicam and 130 patients received diclofenac. A majority of the patients in both groups had a history of OA of the knee, while the remaining patients had a history of OA of the hip. A similar number of patients in both groups had a history of comorbid conditions (eg, gastritis, hypertension, diabetes) ( Table 1) . At baseline, the mean (SD) pain score (WOMAC-CI) was 13.88 (4.47) in the lornoxicam group and 14.15 (4.56) in the diclofenac group. After 4 weeks of treatment, the reduction in pain was significant in both the lornoxicam group (90.6%) and the diclofenac group (88.9%; both, P < 0.05). The reduction in pain was not statistically different between groups (Table II) .
The mean (SD) baseline VAS score was similar in the lornoxicam (8.04 [2.70}) and diclofenac (7.98 [2 .98}) groups. After week 4, the VAS scores were significantly reduced from baseline in the lornoxicam and the diclofenac groups (83.1 % and 79.3%, respectively; both, P < 0.05). There was no statistically significant betweengroup difference (Table II) . At baseline, the mean (SD) stiffness score was 5.25 (2.25) in the lornoxicam group and 5.47 (2.44) in the diclofenac group. After 4 weeks of treatment, stiffness decreased significantly in the lornoxicam and diclofenac groups (80.0% and 78.1 %, respectively; both, P < 0.05 vs baseline). There was no statistically significant betweengroup difference ( Table III) .
The mean (SD) physical function score was 37.96 (9.28) and 38.64 (9.44) in the lornoxicam and diclofenac groups, respectively, at baseline. After 4 weeks of treatment, the physical function score was reduced significantly in both groups (80.4% and 76.5%, respectively; both, P < 0.05 vs baseline). There was no statistically significant between-group difference ( Table III) . *No significant between-group differences were found. t Measured on a scale of 0 to 4 for the following: morning stiffness and stiffness later in the day. r Measured on a scale of 0 to 5 for the following: descending stairs, ascending stairs, rising from sitting, standing, bending to floor, walking on flat surface, getting injout of car, shopping, putting on socks, rising from bed, taking off socks, lying in bed, getting injout of bath, sitting, getting onjoff toilet, heavy domestic duties, and light domestic duties. § p < 0.05 versus baseline.
At baseline, the mean (SD) total WOMAC-OA score in the lornoxicam and diclofenac groups was 57.09 (14.28) and 54.53 (14.60), respectively. After 4 weeks of treatment, the score was significantly reduced in both groups (82.9% and 79.4%, respectively; both, P < 0.05 vs baseline). There was no statistically significant betweengroup difference (Table IV) . Improvement rated at 2 weeks was not statistically different between the 2 groups. In the lornoxicam group, the mean stiffness score was reduced 66.3% (5. (Tables II-IV) .
Based on the global assessment of treatment by the patients after 4 weeks of treatment, 75.0% of patients in the lornoxicam group rated the response to treatment as good to very good compared with 78.3% of patients in the diclofenac group (P = NS). Similarly, 4.2% of patients in the lornoxicam group rated the response as poor compared with 4.3% of patients in the diclofenac group (P = NS) (Figure 2) .
Based on the global assessment of treatment by the investigators after 4 weeks of treatment, 79.2% of patients in the lornoxicam group were rated as having a good to very good response compared with 82.6% in the diclofenac group (P = NS). Similarly, 4.2% of patients in the lornoxicam group and 4.3% in the diclofenac group were rated as having a poor response (P = NS) (Figure 3) .
Twenty of the 137 patients (14.6%) receiving lornoxicam experienced 27 AEs and 25 of the 136 patients (18.4%) receiving diclofenac had 32 AEs. The most commonly reported AEs in both groups were gastritis, nausea and vomiting, headache, and abdominal pain. The intensity of all AEs was rated as mild to moderate and disappeared with continued therapy (Table V) . Both lornoxicam and diclofenac were well tolerated. None of the patients experienced any cardiovascular AEs (eg, edema or increased blood pressure).
No clinically relevant alterations in any of the laboratory findings were observed. None of the patients in either group required rescue analgesics (ie, acetaminophen). All patients were considered to be compliant throughout the course of the study.
DISCUSSION
Pain and impaired mobility result in decreased quality of life for patients with rheumatic diseases. The aim of treatment is rapid, efficient analgesia to achieve the best possible result for these patients. Lornoxicam is a strong analgesic and anti-inflammatory NSAID with balanced COX-l/COX-2 inhibition and excellent tolerability. 4 OA affects millions of people worldwide. Because there is no cure for OA, drug treatment is the primary form of management. This can be achieved with analgesics and anti-inflammatory drugs, such as NSAIDs. 3 After 2 weeks of treatment, improvements in mean stiffness, physical function, pain, and total WOMAC Index scores were not significantly different between the 2 groups.
In a randomized, double-blind, clinical study with lornoxicam 4 mg TID and 8 mg BID, both doses were as effective as diclofenac 50 mg TID for the treatment of patients with OA of the hip and/or knee for ::0-3 months before the start of the study.s The percentage of patients showing improvements in disease activity (~46%) and pain intensity (42%--48%) was similar in all 3 groups. No significant difference in the tolerability of all 3 regimens was found. The results of the present study are con- sistent with the findings of this study.s Diclofenac sodium, a nonselective COX inhibitor, and etoricoxib, a selective COX-2 inhibitor, has been widely used in treating patients with OA.lO The chronic use of diclofenac sodium has been reported to be associated with gastrointestinal AEs.l1
In another double-blind, multicenter, placebo-controlled study in patients with OA, lornoxicam (<;12 mg/d for 4 weeks) appeared to be better tolerated than would be expected for a drug of this class. 3 The authors suggested that lornoxicam was likely to be a useful addition to the drugs available for the treatment of OA. Pain relief scores were significantly better than placebo during treatment with lornoxicam 8 and 12 mg daily. Lornoxicam was well tolerated at both 8 and 12 mg daily. Similar observations were made with 8 mg doses of lornoxicam in the present study.
Lornoxicam has a better gastrointestinal tolerability profile than other oxicams. This has been attributed to lornoxicam's shorter half-life (~4 hours) compared with >24 hours for the other oxicams. 6 Eighteen healthy male volunteers received lornoxicam 8 mg BID or naproxen 500 mg BID administered orally for two 7-day dosing periods. Upper endoscopy was performed by 2 independent investigators at the beginning and end of each dosing regimen. Lornoxicam was associated with significantly less mucosal injury than naproxen in the stomach/duodenal bulb and in the mid/distal duodenum. 12 In the present study, gastrointestinal AEs were reported by a similar number of patients in the lornoxicam and diclofenac groups.
The present study had some limitations. It was undertaken in a restricted group of patients due to several exclusion criteria, preventing extrapolation of the results to the general population. Furthermore, the study was of short duration and only those patients who completed the study were included in the efficacy and safety analysis.
CONCLUSION
The results of the present study suggest that lornoxicam was comparable to diclofenac in effectiveness and tolerability after 4 weeks of treatment in these adult Indian patients with OA of the hip or knee who completed the study.
